3 assets in Binge Eating Disorder

Therapeutic assets addressing Binge Eating Disorder, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Naltrexone Binge Eating Disorder	Yale University	P2/3	B (57)
Tirzepatide Binge Eating Disorder	Johns Hopkins University	P2	CCC (53)